Bausch + Lomb stock rises on survey-driven dry eye focus

Bausch + Lomb stock gains as the eye-care group highlights new survey data on dry eye in perimenopause and menopause, while investors weigh recent revenue growth and valuation metrics.

Bausch + Lomb Corporation (ISIN CA07174N1090) stock has gained ground after the company highlighted new survey findings on dry eye symptoms in perimenopause and menopause, drawing attention to its eye-care portfolio as investors reassess the valuation of the group as of September 2, 2026 according to Baystreet market data.

Survey spotlight supports eye-care narrative

According to a Baystreet stocks-in-play report dated September 2, 2026, Bausch + Lomb announced findings from a new survey showing that dry eye remains one of the least recognized symptoms associated with perimenopause and menopause, despite its prevalence among women in these life stages.

The same Baystreet note states that Bausch + Lomb Corporation shares trading under the ticker T.BLCO closed at 24.66 Canadian dollars on the Toronto Stock Exchange, up 0.66 Canadian dollars on September 1, 2026, highlighting a positive reaction as investors focused on the company’s positioning in women’s eye health.

Latest fundamentals and valuation view

Bausch + Lomb describes itself as a leading global eye health company dedicated to protecting and enhancing sight across all life stages, according to the company’s own investor relations overview page, which confirms its listing on the New York Stock Exchange and Toronto Stock Exchange under the symbol BLCO.

An analysis on GuruFocus dated September 2, 2026 notes that BLCO currently trades at a price-to-sales ratio of 1.2, slightly below its historical median of about 1.3, suggesting that the market values the company at a modest discount to its long-run revenue multiple.

The same valuation piece estimates Bausch + Lomb’s intrinsic value at 18.27 United States dollars per share based on the proprietary GF Value metric, compared with a contemporaneous market price of 17.88 United States dollars per share, implying that the stock was about 2.1 percent undervalued relative to this model as of early September 2026.

GuruFocus also points out that earnings-based metrics such as price-to-earnings are not yet applicable because Bausch + Lomb remains loss-making, which means revenue growth and margin improvement are central for investors monitoring BLCO stock over the next few quarters.

Read more about BLCO

Dry eye products in focus

Bausch + Lomb’s portfolio includes a broad range of prescription and over-the-counter eye-care products, and the newly highlighted survey on dry eye in perimenopausal and menopausal women underscores the role of lubricating eye drops and related therapies in addressing this segment.

For retail investors, the survey-driven focus on dry eye can be seen as a reminder that Bausch + Lomb has exposure to chronic, recurring conditions where patients often rely on regular purchases of eye-care products, supporting a revenue base that is less cyclical than some other healthcare categories.

Bausch + Lomb stock price snapshot

Based on the Baystreet report dated September 2, 2026, Bausch + Lomb stock closed at 24.66 Canadian dollars on the Toronto Stock Exchange on September 1, 2026, representing a gain of 0.66 Canadian dollars during that trading session as BLCO shares reacted positively to the company's communication around dry eye survey results.

Bausch + Lomb at a glance

• Company: Bausch + Lomb Corporation
• ISIN: CA07174N1090
• Ticker: BLCO
• Trading venue: NYSE and TSX
• Price (as of September 1, 2026): 24.66 CAD
• Sector / Industry: Health Care / Eye care
• Index membership: Not specified major benchmark index